Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 6/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | BRD2 | P25440 | 1/20 | 0.51 |
| ▸ | BRD3 | Q15059 | 1/20 | 0.51 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.51 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.50 |
| ▸ | PDE1A | P54750 | 1/20 | 0.49 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.49 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.49 |
| ▸ | PARN | O95453 | 1/20 | 0.48 |
| ▸ | CNOT7 | Q9UIV1 | 1/20 | 0.48 |
| ▸ | PDE4A | P27815 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22105440 | 0.89 | BRD4 (0.62) | BRD4MEN1KMT2APOLBKDM4E | |
| SCHEMBL20656006 | 0.89 | BRD4 (0.50) | BRD4MEN1KMT2APOLBKDM4E | |
| SCHEMBL20652786 | 0.88 | BRD4 (0.49) | BRD4MEN1KMT2APOLBKDM4E | |
| SCHEMBL28749938 | 0.88 | LMNA (0.64) | BRD4MEN1KMT2APOLBKDM4E | |
| SCHEMBL7605036 | 0.84 | BRD4 (0.68) | BRD4MEN1KMT2APOLBKDM4E | |
| SCHEMBL5773292 | 0.84 | BRD4 (0.61) | BRD4MEN1KMT2APOLBKDM4E | |
| SCHEMBL2795748 | 0.83 | POLB (0.75) | BRD4MEN1KMT2APOLBKDM4E | |
| SCHEMBL556233 | 0.83 | BRD4 (0.82) | BRD4MEN1KMT2APOLBKDM4E | |
| SCHEMBL554932 | 0.82 | BRD4 (0.81) | BRD4MEN1KMT2APOLBKDM4E | |
| SCHEMBL27794931 | 0.82 | POLB (0.73) | BRD4MEN1KMT2APOLBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3894410-B1 | SUBSTITUTED XANTHINE DERIVATIVES | BOEHRINGER INGELHEIM INT (DE) | 2023-10-11 | — | — | EP | disclosed |
| US-20220177479-A1 | NOVEL SUBSTITUTED XANTHINE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2022-06-09 | — | — | US | disclosed |
| EP-3652176-B1 | SUBSTITUTED XANTHINE DERIVATIVES | BOEHRINGER INGELHEIM INT (DE) | 2021-12-15 | — | — | EP | disclosed |
| WO-2020120450-A1 | SUBSTITUTED XANTHINE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2020-06-18 | — | — | WO | disclosed |
| US-10329292-B2 | Substituted xanthine derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-06-25 | — | — | US | disclosed |
| US-20190016722-A1 | NOVEL SUBSTITUTED XANTHINE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-01-17 | — | — | US | disclosed |
| WO-2019011802-A1 | NOVEL SUBSTITUTED XANTHINE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2019-01-17 | — | — | WO | disclosed |
| US-20140057901-A1 | XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2014-02-27 | — | — | US | disclosed |
| EP-2298769-B1 | Xanthin derivatives, their production and utilisation as medicine | BOEHRINGER INGELHEIM PHARMA (DE) | 2013-10-30 | — | — | EP | disclosed |
| US-20130165428-A1 | XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2013-06-27 | — | — | US | disclosed |
| US-20040087587-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-05-06 | — | — | US | disclosed |
| US-20040077645-A1 | Dipeptidyl aminopeptidase inhibitors; diabetes mellitus, arthritis, obesity, allograft transplantation and osteoporosis treatment | BOEHRINGER INGELHEIM PHARMA GMBH & CO KG (DE) | 2004-04-22 | — | — | US | disclosed |
| EP-1368349-A1 | XANTHINE DERIVATIVE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-12-10 | — | — | EP | disclosed |
| US-20020198205-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-12-26 | — | — | US | disclosed |
| EP-0812844-B1 | Use of theophyllin derivatives for the treatment and prophylaxis fo shock conditions, novel xanthine compounds and processes for the production thereof | HOECHST AG (DE) | 2002-10-23 | — | — | EP | disclosed |
| WO-2002068420-A1 | XANTHINE DERIVATIVE, PRODUCTION AND USE THEREOF AS A MEDICAMENT | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-09-06 | — | — | WO | disclosed |
| CN-1066146-C | Use of theophylline derivatives for curing and preventing shock state, xanthine derivatives and preparation thereof | AVENTIS PHARMACEUTICALS AG (DE) | 2001-05-23 | — | — | CN | disclosed |
| US-6214992-B1 | THEOPHYLLINE DERIVATIVES HAVING AT LEAST ONE ETHER FUNCTION IN METHYL RADICAL; XANTHINE COMPOUNDS WITH THIS SUBSTITUTION PATTERN USED AS ANTISHOCK TREATMENT | HOECHST AKTIENGESELLSCHAFT (DE) | 2001-04-10 | — | — | US | disclosed |
| CN-1169993-A | Use of theophylline derivatives for curing and preventing shock state, xanthine derivatives and preparation thereof | HOECHST AG (DE) | 1998-01-14 | — | — | CN | disclosed |
| EP-0812844-A2 | Use of theophyllin derivatives for the treatment and prophylaxis fo shock conditions, novel xanthine compounds and processes for the production thereof | HOECHST AKTIENGESELLSCHAFT (DE) | 1997-12-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040087587-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP3, DPP7 | BRD4 3145/4885MEN1 3272/4885KMT2A 3433/4885 |
| US-20130165428-A1 | XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP4, DPP3, DPP7 | BRD4 3056/4885MEN1 2867/4885KMT2A 3439/4885 |
| US-10329292-B2 | Substituted xanthine derivatives | TRPC5, TRPV1, TRPC4 | BRD4 1689/4885MEN1 4272/4885KMT2A 4180/4885 |
| US-20140057901-A1 | XANTHINE DERIVATIVES, THE PREPARATION THEREOF AND THEIR USE AS PHARMACEUTICAL COMPOSITIONS | DPP4, DPP3, DPP7 | BRD4 3021/4885MEN1 3162/4885KMT2A 3475/4885 |
| US-20020198205-A1 | Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions | DPP4, DPP3, DPP7 | BRD4 3145/4885MEN1 3272/4885KMT2A 3433/4885 |
| US-20190016722-A1 | NOVEL SUBSTITUTED XANTHINE DERIVATIVES | TRPC5, TRPC4, TRPV1 | BRD4 1686/4885MEN1 4447/4885KMT2A 4155/4885 |
| US-20040077645-A1 | Dipeptidyl aminopeptidase inhibitors; diabetes mellitus, arthritis, obesity, allograft transplantation and osteoporosis treatment | DPP4, DPP3, DPP7 | BRD4 3499/4885MEN1 4235/4885KMT2A 3251/4885 |
| US-20220177479-A1 | NOVEL SUBSTITUTED XANTHINE DERIVATIVES | TRPC5, TRPC4, TRPM5 | BRD4 2381/4885MEN1 3627/4885KMT2A 4516/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.